Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
NovoCure Limited stock logo
NVCR
NovoCure
$12.34
+2.4%
$14.57
$10.87
$83.60
$1.33B0.421.70 million shs1.32 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$206.15
+0.2%
$230.76
$180.93
$348.67
$7.96B0.51293,139 shs336,365 shs
Teleflex Incorporated stock logo
TFX
Teleflex
$211.17
+0.0%
$223.09
$177.63
$276.43
$9.94B1.11251,752 shs201,415 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$35.12
+0.4%
$30.51
$13.82
$40.74
$2.26B1.121.25 million shs997,284 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
NovoCure Limited stock logo
NVCR
NovoCure
+2.36%+2.41%-6.52%-9.86%-79.76%
Penumbra, Inc. stock logo
PEN
Penumbra
+0.22%-1.24%-6.32%-17.71%-27.64%
Teleflex Incorporated stock logo
TFX
Teleflex
-0.01%+1.40%-3.86%-13.77%-21.31%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+0.43%+10.61%+16.68%+52.76%-3.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
2.1065 of 5 stars
0.00.01.73.80.61.72.5
NovoCure Limited stock logo
NVCR
NovoCure
4.3029 of 5 stars
4.34.00.04.50.62.50.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.9494 of 5 stars
4.43.00.03.82.62.53.1
Teleflex Incorporated stock logo
TFX
Teleflex
4.8276 of 5 stars
3.33.01.73.92.82.52.5
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.8304 of 5 stars
2.21.00.04.93.50.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
2.56
Moderate Buy$31.13152.23% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.78
Moderate Buy$304.4547.69% Upside
Teleflex Incorporated stock logo
TFX
Teleflex
2.60
Moderate Buy$267.5026.68% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.36
Hold$39.4512.34% Upside

Current Analyst Ratings

Latest HRC, NVCR, PEN, TNDM, and TFX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$34.00 ➝ $45.00
4/23/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $40.00
4/10/2024
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $28.00
4/3/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$49.00 ➝ $42.00
4/3/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$290.00
4/3/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$31.00 ➝ $38.00
3/27/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$21.00
3/27/2024
NovoCure Limited stock logo
NVCR
NovoCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$22.00 ➝ $24.00
3/26/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$24.00 ➝ $37.00
3/22/2024
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$290.00 ➝ $280.00
3/19/2024
NovoCure Limited stock logo
NVCR
NovoCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$15.00 ➝ $17.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
NovoCure Limited stock logo
NVCR
NovoCure
$509.34M2.61N/AN/A$3.39 per share3.64
Penumbra, Inc. stock logo
PEN
Penumbra
$1.06B7.54$2.83 per share72.75$30.55 per share6.75
Teleflex Incorporated stock logo
TFX
Teleflex
$2.97B3.34$18.84 per share11.21$94.49 per share2.23
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$747.72M3.03N/AN/A$4.81 per share7.30

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.95N/AN/AN/A-40.65%-51.63%-17.90%5/2/2024 (Confirmed)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$2.3189.2451.802.038.59%7.49%5.60%5/7/2024 (Confirmed)
Teleflex Incorporated stock logo
TFX
Teleflex
$356.33M$7.5328.0413.892.0211.98%14.98%8.87%5/2/2024 (Confirmed)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$222.61M-$3.44N/AN/AN/A-29.77%-31.48%-10.75%5/2/2024 (Confirmed)

Latest HRC, NVCR, PEN, TNDM, and TFX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Penumbra, Inc. stock logo
PEN
Penumbra
$0.42N/A-$0.42N/AN/AN/A  
5/2/2024N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$0.42N/A+$0.42N/AN/AN/A  
5/2/2024N/A
Teleflex Incorporated stock logo
TFX
Teleflex
$3.07N/A-$3.07N/AN/AN/A  
5/2/2024N/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.80N/A+$0.80N/AN/AN/A  
2/22/2024Q4 2023
NovoCure Limited stock logo
NVCR
NovoCure
-$0.53-$0.45+$0.08-$0.45$133.80 million$133.80 million      
2/22/2024Q4 2023
Penumbra, Inc. stock logo
PEN
Penumbra
$0.71$0.76+$0.05$0.14$286.62 million$284.68 million      
2/22/2024Q4 23
Teleflex Incorporated stock logo
TFX
Teleflex
$3.26$3.38+$0.12$6.10$769.01 million$773.90 million      
2/21/2024Q4 2023
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.23-$0.27-$0.04-$0.08$204.86 million$196.80 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.360.64%N/A18.06%N/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A

Latest HRC, NVCR, PEN, TNDM, and TFX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/22/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.57%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
NovoCure Limited stock logo
NVCR
NovoCure
1.57
5.78
5.56
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.06
3.49
Teleflex Incorporated stock logo
TFX
Teleflex
0.39
2.32
1.29
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.91
3.83
3.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
NovoCure Limited stock logo
NVCR
NovoCure
5.67%
Penumbra, Inc. stock logo
PEN
Penumbra
5.30%
Teleflex Incorporated stock logo
TFX
Teleflex
1.43%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,453107.61 million101.51 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,20038.70 million36.65 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,50047.10 million46.43 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,40064.56 million62.95 millionOptionable

HRC, NVCR, PEN, TNDM, and TFX Headlines

SourceHeadline
Jennison Associates LLC Has $38.18 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Jennison Associates LLC Has $38.18 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - April 25 at 7:19 AM
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded to "Outperform" by SVB LeerinkTandem Diabetes Care (NASDAQ:TNDM) Upgraded to "Outperform" by SVB Leerink
marketbeat.com - April 25 at 7:11 AM
Tandem Diabetes Care (TNDM) to Release Earnings on ThursdayTandem Diabetes Care (TNDM) to Release Earnings on Thursday
americanbankingnews.com - April 25 at 2:14 AM
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $40.00 at Stifel NicolausTandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $40.00 at Stifel Nicolaus
americanbankingnews.com - April 24 at 4:02 AM
Tandem Diabetes Care IncTandem Diabetes Care Inc
morningstar.com - April 23 at 10:56 PM
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $40.00 by Analysts at Stifel NicolausTandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $40.00 by Analysts at Stifel Nicolaus
marketbeat.com - April 23 at 1:49 PM
Tandem Diabetes Care (NASDAQ:TNDM) Shares Up 7.9%Tandem Diabetes Care (NASDAQ:TNDM) Shares Up 7.9%
marketbeat.com - April 23 at 1:25 PM
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) & IceCure Medical (NASDAQ:ICCM)Contrasting Tandem Diabetes Care (NASDAQ:TNDM) & IceCure Medical (NASDAQ:ICCM)
americanbankingnews.com - April 20 at 2:04 AM
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at StockNews.comTandem Diabetes Care (NASDAQ:TNDM) Upgraded at StockNews.com
americanbankingnews.com - April 19 at 2:14 AM
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Mirae Asset Global Investments Co. Ltd.Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Mirae Asset Global Investments Co. Ltd.
marketbeat.com - April 17 at 4:44 AM
Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 2.9%Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 2.9%
marketbeat.com - April 15 at 1:55 PM
Raymond James & Associates Purchases 51,721 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Raymond James & Associates Purchases 51,721 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - April 15 at 4:26 AM
Validea Detailed Fundamental Analysis - TNDMValidea Detailed Fundamental Analysis - TNDM
nasdaq.com - April 14 at 11:34 AM
Tandem Diabetes Care (NASDAQ:TNDM) Downgraded by StockNews.com to SellTandem Diabetes Care (NASDAQ:TNDM) Downgraded by StockNews.com to Sell
marketbeat.com - April 11 at 11:12 PM
Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024
businesswire.com - April 9 at 4:05 PM
Whats Driving Tandem Diabetes Care Incs Surprising 25% Stock Rally?What's Driving Tandem Diabetes Care Inc's Surprising 25% Stock Rally?
gurufocus.com - April 9 at 12:02 PM
Bullish Tandem Diabetes Care Insiders Loaded Up On US$725.5k Of StockBullish Tandem Diabetes Care Insiders Loaded Up On US$725.5k Of Stock
finance.yahoo.com - April 9 at 8:55 AM
1 Beaten-Down Stock That Could Make You Richer1 Beaten-Down Stock That Could Make You Richer
fool.com - April 7 at 12:07 PM
Should You Invest in Tandem Diabetes Care (TNDM)?Should You Invest in Tandem Diabetes Care (TNDM)?
finance.yahoo.com - April 5 at 9:49 AM
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $38.00Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $38.00
marketbeat.com - April 3 at 3:22 PM
Tandem Mobi automated insulin pump wins FDA nod for expanded pediatric useTandem Mobi automated insulin pump wins FDA nod for expanded pediatric use
drugdeliverybusiness.com - April 2 at 2:43 PM
Chicago Capital LLC Has $14.11 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Chicago Capital LLC Has $14.11 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - April 2 at 6:37 AM
Tandem Diabetes Care (NASDAQ:TNDM)  Shares Down 6.1% Tandem Diabetes Care (NASDAQ:TNDM) Shares Down 6.1%
marketbeat.com - April 1 at 3:48 PM
Tandem Diabetes (TNDM) Gains From Innovation Amid Macro IssuesTandem Diabetes (TNDM) Gains From Innovation Amid Macro Issues
zacks.com - April 1 at 11:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Hill-Rom logo

Hill-Rom

NYSE:HRC
Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.
NovoCure logo

NovoCure

NASDAQ:NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Penumbra logo

Penumbra

NYSE:PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Teleflex logo

Teleflex

NYSE:TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Tandem Diabetes Care logo

Tandem Diabetes Care

NASDAQ:TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.